All In Biotech

Drug Trial Radar · NCT05851014

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting

Last checked: Nov 19, 2026Latest source record: May 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Jan 14, 2022

Primary completion

Jan 30, 2026

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Genor Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
May 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy

Conditions

  • Breast Cancer

Interventions

  • GB491 combined with LetrozoleDrug

    Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)

  • Placebo combined with LetrozoleDrug

    Patients were randomized to receive placebo orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed PFS based on RECIST v1.1Time frame: Approximately 60 months

Locations

52 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

  • The First Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Anhui Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • The Second Hosptial of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Betjing Tiantan Hosptial,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Chinese PLA General Hospial

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Hospital of Wenzhou Medical University

    Wenzhou, Fujian, China · Recruiting

  • The First Affiliated Hosptial of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • The First People's Hospital of Foshan

    Foshan, Guangdong, China · Recruiting

  • Sun Yat-Sen University Cancer Center(Huangpu Campus)

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-Sen University Cancer Center(Yuexiu Campus)

    Guangzhou, Guangdong, China · Recruiting

  • Maternal and Child Healh Hosptal of Guangdong Provrce

    Guangzhou, Guangdong, China · Recruiting

  • Meizhou People's Hosptial

    Meizhou, Guangdong, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China · Recruiting

  • Xingtai People's Hospital

    Xingtai, Hebei, China · Recruiting

  • The First Affiliated Hosptial of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China · Recruiting

  • The First Affiliated Hosptial of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The Nanchang theird people's Hosptial

    Nanchang, Jiangxi, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Shangrao People's Hospital

    Shangrao, Jiangxi, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Recruiting

  • General Hospital of Ningxia Medical University

    Yingchuan, Ningxia, China · Recruiting

  • Xi'an International Medical Center Hospital

    Xi'an, Shaanxi, China · Recruiting

  • Jinan Central Hospital

    Jinan, Shandong, China · Recruiting

  • Shandong Provincial Hospital

    Jinan, Shandong, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, China · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.